Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Official title

A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy

Study identification

NCT ID

NCT06580314

Recruitment status

Recruiting

Study type

Interventional

Phase

Phase 3

Lead sponsor

NRG Oncology

Other

Enrollment

880 participants

Conditions and interventions

Eligibility (public fields only)

Age range

18 Years and older

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Mar 11, 2025

Primary completion

Dec 30, 2034

Completion

Dec 30, 2034

Last update posted

Mar 23, 2026

2025 – 2034

United States locations

U.S. sites

658

U.S. states

46

U.S. cities

450

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.